Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Viremia preceding multiple sclerosis: Two nested case-control studies.

Hultin E, Mühr LSA, Bzhalava Z, Hortlund M, Lagheden C, Sundström P, Dillner J.

Virology. 2018 Jul;520:21-29. doi: 10.1016/j.virol.2018.04.006. Epub 2018 May 14.

PMID:
29772404
2.

Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APCmin/+ mice.

Akeus P, Szeponik L, Ahlmanner F, Sundström P, Alsén S, Gustavsson B, Sparwasser T, Raghavan S, Quiding-Järbrink M.

Cancer Immunol Immunother. 2018 Jul;67(7):1067-1077. doi: 10.1007/s00262-018-2161-9. Epub 2018 Apr 18.

PMID:
29671006
3.

Release of transcriptional repression through the HCR promoter region confers uniform expression of HWP1 on surfaces of Candida albicans germ tubes.

Kim S, Nguyen QB, Wolyniak MJ, Frechette G, Lehman CR, Fox BK, Sundstrom P.

PLoS One. 2018 Feb 13;13(2):e0192260. doi: 10.1371/journal.pone.0192260. eCollection 2018.

4.

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.

de Flon P, Söderström L, Laurell K, Dring A, Sundström P, Gunnarsson M, Svenningsson A.

PLoS One. 2018 Feb 8;13(2):e0192516. doi: 10.1371/journal.pone.0192516. eCollection 2018.

5.

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L, Zetterberg H, Sundström P, Axelsson M, Khademi M, Gunnarsson M, Malmeström C, Svenningsson A, Olsson T, Piehl F, Blennow K, Lycke J.

Neurology. 2017 Nov 28;89(22):2230-2237. doi: 10.1212/WNL.0000000000004683. Epub 2017 Oct 27.

6.

Managing Epstein-Barr virus and other risk factors in MS-Future perspectives.

Sundström P.

Acta Neurol Scand. 2017 Nov;136 Suppl 201:31-33. doi: 10.1111/ane.12841. Review.

PMID:
29068493
7.

How to minimize the risk for headache? A lumbar puncture practice questionnaire study.

Salzer J, Rajda C, Sundström P, Vågberg M, Vécsei L, Svenningsson A.

Ideggyogy Sz. 2016 Nov 30;69(11-12):397-402. doi: 10.18071/isz.69.0397.

PMID:
29733557
8.

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A.

Neurology. 2016 Nov 15;87(20):2074-2081. Epub 2016 Oct 19.

9.

The impact of adjusted work conditions and disease-modifying drugs on work ability in multiple sclerosis.

Wickström A, Fagerström M, Wickström L, Granåsen G, Dahle C, Vrethem M, Sundström P.

Mult Scler. 2017 Jul;23(8):1137-1147. doi: 10.1177/1352458516671818. Epub 2016 Oct 6.

PMID:
27758955
10.

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.

Røsjø E, Lossius A, Abdelmagid N, Lindstrøm JC, Kampman MT, Jørgensen L, Sundström P, Olsson T, Steffensen LH, Torkildsen Ø, Holmøy T.

Mult Scler. 2017 Mar;23(3):395-402. doi: 10.1177/1352458516654310. Epub 2016 Jul 11.

PMID:
27325604
11.

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

de Flon P, Gunnarsson M, Laurell K, Söderström L, Birgander R, Lindqvist T, Krauss W, Dring A, Bergman J, Sundström P, Svenningsson A.

Neurology. 2016 Jul 12;87(2):141-7. doi: 10.1212/WNL.0000000000002832. Epub 2016 Jun 17.

PMID:
27316241
12.

Regulatory T Cells from Colon Cancer Patients Inhibit Effector T-cell Migration through an Adenosine-Dependent Mechanism.

Sundström P, Stenstad H, Langenes V, Ahlmanner F, Theander L, Ndah TG, Fredin K, Börjesson L, Gustavsson B, Bastid J, Quiding-Järbrink M.

Cancer Immunol Res. 2016 Mar;4(3):183-93. doi: 10.1158/2326-6066.CIR-15-0050. Epub 2016 Jan 19.

13.

Vitamin D and axonal injury in multiple sclerosis.

Sandberg L, Biström M, Salzer J, Vågberg M, Svenningsson A, Sundström P.

Mult Scler. 2016 Jul;22(8):1027-31. doi: 10.1177/1352458515606986. Epub 2015 Oct 13.

PMID:
26462862
14.

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.

Wickström A, Sundström P, Wickström L, Dahle C, Vrethem M, Svenningsson A.

Mult Scler J Exp Transl Clin. 2015 Sep 22;1:2055217315608203. doi: 10.1177/2055217315608203. eCollection 2015 Jan-Dec.

15.

Human Mucosa-Associated Invariant T Cells Accumulate in Colon Adenocarcinomas but Produce Reduced Amounts of IFN-γ.

Sundström P, Ahlmanner F, Akéus P, Sundquist M, Alsén S, Yrlid U, Börjesson L, Sjöling Å, Gustavsson B, Wong SB, Quiding-Järbrink M.

J Immunol. 2015 Oct 1;195(7):3472-81. doi: 10.4049/jimmunol.1500258. Epub 2015 Aug 21.

16.

Vitamin D and multiple sclerosis—from epidemiology to prevention.

Sundström P, Salzer J.

Acta Neurol Scand. 2015;132(199):56-61. doi: 10.1111/ane.12432. Review.

PMID:
26046560
17.

Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden.

Svenningsson A, Salzer J, Vågberg M, Sundström P, Svenningsson A.

Acta Neurol Scand. 2015 Dec;132(6):389-94. doi: 10.1111/ane.12408. Epub 2015 Apr 10.

PMID:
25857351
18.

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Svenningsson A, Sundstrom P, Salzer J, Vagberg M.

Neurology. 2014 Nov 25;83(22):2099-100. doi: 10.1212/01.wnl.0000457455.74798.9a. No abstract available. Erratum in: Neurology. 2015 Feb 24;84(8):862.

PMID:
25422402
19.

Lumbar puncture preferences among Swedish neurologists.

Salzer J, Sundström P, Vågberg M, Svenningsson A.

Neurol Res. 2015 Jan;37(1):92-4. doi: 10.1179/1743132814Y.0000000442. Epub 2014 Sep 12.

PMID:
25213597
20.

Targeting Epstein-Barr virus infection as an intervention against multiple sclerosis.

Jons D, Sundström P, Andersen O.

Acta Neurol Scand. 2015 Feb;131(2):69-79. doi: 10.1111/ane.12294. Epub 2014 Sep 11. Review.

PMID:
25208981

Supplemental Content

Loading ...
Support Center